Scarica l'app Stockscreener
0.27
24.51%
-0.0413
Dopo l'orario di chiusura:
.27
Zyversa Therapeutics Inc Borsa (ZVSA) Ultime notizie
ZyVersa Therapeutics Inc. Stock Analysis and ForecastConsistently high returns - PrintWeekIndia
What analysts say about ZyVersa Therapeutics Inc. stockExceptional profit potential - Autocar Professional
Is ZyVersa Therapeutics Inc. a good long term investmentRapid-fire capital growth - Autocar Professional
What drives ZyVersa Therapeutics Inc. stock priceRapidly growing investment returns - jammulinksnews.com
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter - GlobeNewswire
ZyVersa secures $12 million in financing to advance kidney disease trials - Investing.com
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq
ZyVersa Therapeutics Raises $12M to Accelerate Breakthrough Kidney and Inflammatory Disease Treatments - Stock Titan
ZVSA’s Market Whiplash: -93.65% YTD Decline, -52.27% Plunge in 30 Days - investchronicle.com
Why ZyVersa Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com India
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market By Investing.com - Investing.com South Africa
How ZyVersa Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
What makes ZyVersa Therapeutics Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen - Defense World
ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis - MarketScreener
Why Did ZyVersa Therapeutics Plunge 10% Despite Funding Boost? - AInvest
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 17.4% – Time to Buy? - Defense World
ZyVersa Therapeutics Supports FDA-Authorized Emergency - GlobeNewswire
ZyVersa Secures $2 Mln Through Warrant Inducement Deal With Institutional Investor - Nasdaq
ZVSA’s Stock Journey: What Investors Need to Know About ZyVersa Therapeutics Inc’s Performance - investchronicle.com
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? - Benzinga
Intensity Therapeutics Inc’s Shares Reel: -85.34% Quarterly Revenue Decline Amid 7.38M Market Cap - investchronicle.com
ZyVersa announces warrant inducement transaction for $2M in gross proceeds - TipRanks
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds - GlobeNewswire
Biotech ZyVersa Raises $2M in Strategic Warrant Deal to Advance Drug Development Pipeline - Stock Titan
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
ZyVersa’s VAR 200 approved for emergency use in rare kidney disease - Investing.com
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis - The Manila Times
FDA Grants Emergency Access to ZyVersa's VAR 200 Drug for Ultra-Rare Kidney Disease Treatment - Stock Titan
ZyVersa’s VAR 200 approved for emergency use in rare kidney disease By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Launches Phase 2a Study for DKD Treatment | ZVSA Stock News - GuruFocus
ZyVersa begins patient recruitment for kidney disease drug trial - Investing.com
ZyVersa begins patient recruitment for kidney disease drug trial By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Secures Funding Deal to Advance Kidn - GuruFocus
ZyVersa enters $10 million share purchase agreement with WVH By Investing.com - Investing.com UK
ZyVersa Therapeutics announcs share purchase agreement for up to $10M - TipRanks
Critical Analysis: ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Schrödinger (NASDAQ:SDGR) - Defense World
0.97%
0.22%
Capitalizzazione:
|
Volume (24 ore):